{
    "clinical_study": {
        "@rank": "136258", 
        "brief_summary": {
            "textblock": "The purpose of this clinical research study is to learn if the clinical effects of combined\n      Chinese herbal medicine with endocrine therapy is better than endocrine therapy alone in\n      improving the quality of life and shrinking and slowing the growth of the cancer in women\n      with breast cancer bone metastasis."
        }, 
        "brief_title": "Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer", 
        "condition": [
            "Breast Cancer", 
            "Bone Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasm Metastasis", 
                "Bone Neoplasms", 
                "Bone Marrow Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Evaluate the effect of the Chinese herbal medicine on  relieving the bone pain for\n           patients with breast cancer bone metastasis.\n\n        -  Evaluate the effect of the Chinese herbal medicine on improving the quality of life and\n           shrinking and slowing the growth of the cancer in women with breast cancer bone\n           metastasis.\n\n      OUTLINE: This is a randomized,multicentric, placebo-controlled, double-blind study. Patients\n      are dynamic randomized to one of two treatment arms.\n\n        -  Arm I:Patients receive  traditional Chinese medicine(trial drugs) and endocrine therapy\n           for 3 months.\n\n        -  Arm II:Patients receive placebo and endocrine therapy for 3 months. All patients will\n           be followed up for another 3 months with the trial drugs and endocrine therapy.\n\n      According to the sample size estimate:There are 296 patients (148 per treatment arm)will be\n      collected in this trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed breast cancer and hormone receptor positive.\n\n          -  Bone metastasis and have a measurable foci.\n\n          -  TCM syndrome type is deficiency of both vital energy and Yin ;maladjustment     of\n             ChongRen with deficiency Yang syndrome.\n\n          -  The Karnofsky score \u226560.\n\n          -  VAS score \u22653.\n\n          -  Expected survival at least 6 months or greater.\n\n          -  Age between 20 to 70(include 20 and 70).\n\n          -  The function of cardiovascular,hepar,renal and hematopoieses is relatively   normal.\n\n        Exclusion Criteria:\n\n          -  Women during the pregnancy or breast feeding.\n\n          -  With a cardiovascular,hepar,renal,hematopoieses or other serious complications.\n\n          -  Be allergic to the trial drugs.\n\n          -  Participating in other trials."
            }, 
            "gender": "Female", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011880", 
            "org_study_id": "ZYSNXD-CC-ZDYJ043"
        }, 
        "intervention": {
            "description": "Dietary Supplement:Experiment group:\nFructus Cnidii,Psoralea Corylifolin L.\uff0cmonkshood\n-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g\uff0cPsoralea Corylifolin L. 15g\uff0cmonkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity\nBreast Cancer Postoperative Prescription\n-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity\nDietary Supplement:Contrast Group:\nBreast Cancer Postoperative Prescription\n-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity", 
            "intervention_name": "Chinese Herbs", 
            "intervention_type": "Dietary Supplement", 
            "other_name": [
                "Fructus Cnidii", 
                "Psoralea Corylifolin L.", 
                "monkhsood", 
                "Breast Cancer Postoperative Prescription"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "breast cancer", 
            "bone metastasis", 
            "traditional Chinese medicine(TCM)"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "official_title": "Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer", 
        "overall_status": "Temporarily not available", 
        "oversight_info": {
            "authority": "China: Science and Technology Commission of Shanghai Municipality"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011880"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Shanghai University of Traditional Chinese Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai University of Traditional Chinese Medicine", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "September 2013"
    }
}